Premaitha Share Discussion Threads

[the monkster] 19/12/2017 16:53

bye bye more like

[hjb1] 15/12/2017 11:10

'news has been leaked' ha ha! must be good news then as only ONE measly sell atm..! lol Good interims next week maybe?

[thinkbig?] 15/12/2017 09:38

Looks like news has been leaked. Low of lows lol.

[small crow] 14/12/2017 15:29

... and marked down on almost no volume.

[nw99] 11/12/2017 10:25

We have positive news now onwards and upwards it's well oversold

[thinkbig?] 11/12/2017 09:56

Dips it's been dipping for years lol

[nw99] 11/12/2017 08:49

No need for a placing just buy any dips

[nw99] 11/12/2017 08:03

Cracking news

[captain_kurt] 11/12/2017 07:13

More good news today. Revenue from these labs £1M+

'Key thing for me is that this is in Europe. Key concrete vote of confidence that the existing circa £2m sales in Europe have a realistic contingency plan the new distributors believe in'

Roll on the results this week which should show excellent growth.

[hjb1] 02/12/2017 10:57

might take another look, as it seems a good price to get in right now?

[dave444] 02/12/2017 07:58

Do not think I am

[hjb1] 01/12/2017 21:58

Dave444, I am glad I did not take your tip with TERN, how's your investment there?? Better off here mate..lol

[hjb1] 30/11/2017 15:29

well that is the stance atm, could change though, a deal will be best for all concerned.The anti-trust against Illumina might sway them to agree a license.

[christopher logsdon] 30/11/2017 11:47

Are they planning on appealing the decision?

[whites123] 30/11/2017 10:27

What a shame about NIPT.... (I had held since Vialogy days)

ODX could be a savior though... DYOR....

ODX : OMEGA DIAGNOSTICS.

Announced yesterday they have obtained the CE approval to sell the long awaited and anticipated AIDs testing kit.
This breakthrough announcement came 2 days before World Aids Day.
"Transformational news".



The stock is so lightly held it will potentially rocket exactly the same way PYC has.

On top of this great news from ODX we also still have news on their Malaria tests.

Results are due in 2 weeks time and its expected and anticipated they will surpass last eyars which showed gains in revenues and sales.

finapp have re-iterated their buy stance and target of 30p (Which is extremely cheap)

Once these Aid tests start rolling off its a change of fortune for ODX.

Research analysts at finnCap have GBX 30.00 PT on Omega Diagnostics Group PLC (LON:ODX). finnCap’s PT means a potential upside of 42.86% from the company’s last close price. The rating was revealed in an analyst report on Wednesday, 29 November.

hxxps://www.thetimes.co.uk/article/hiv-test-passes-key-hurdle-for-omega-diagnostics-2nnz56jnh

hxxp://www.insider.co.uk/news/omega-diagnostics-gains-ce-marking-11605971

[hjb1] 30/11/2017 09:30

just one rns to say a deal has been done with Illumina will do the trick.

[christopher logsdon] 30/11/2017 09:02

Bought into this at 20p have average down twice would love to see this hit 20p+

[hjb1] 29/11/2017 15:27

it will be 30p+ if they can sort a deal with Illumina, by the end of Jan if they hurry up!

[christopher logsdon] 29/11/2017 15:19

10p + March/April

[nw99] 29/11/2017 15:00

Short term test 7.75p looking at the charts

[small crow] 29/11/2017 12:15

Definitely.

[nw99] 29/11/2017 12:05

Plenty of buyers stock oversold here ?

[hjb1] 28/11/2017 15:31

interesting thoughts from Flipper on lse;
If you work on Natera's (mcap $712m +)figures it would put Prem at 40p+ today..Just need a settlement with Illumina and it's off we go!

I do not think the significance of the 11,000 test volume was fully appreciated here.

Test volumes for the first half are expected to be in excess of 22,000 (H1 2016: 11,000 tests; full year to March 2017: 24,000 tests) . Premaitha 1st half test volumes, excluding Yourgene, were up 140% to c.15,000 tests.

Now you can see the 11,000 announced today is a big jump up

How does circa 50k to 60k test volumes compare to the rest of the NIPT market?:
(a) Ariosa (Roche) including licensees: 213,300 tests (22% Market share)
(b) Sequenom: 153,900 tests
(c) Verinata (Illumina): 192,000 tests
(d) IP Pool (Sequenom & Illumina): 489,300 tests (50% Market share)
(e) Natera including licensees: 254,900 tests (26% Market share)

You can google what the market capitalisation so Natera's is US$ 712.66M the number of tests yield.